Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.…
Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High?
Pharvaris (NASDAQ: PHVS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 168 employees.
The shares were at 31.28 USD on 20 November 2026, up 29.7% over 52 weeks. Its 52-week range is 22.77 USD to 43.25 USD: the price is 27.7% below the high and 37.3% above the low.
Its market capitalisation is 2.21B USD.
Pharvaris reports return on equity of -64.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 282.13M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 14 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 58.27 USD is 86.3% above the current price. The next earnings report is expected on 1 April 2027.